RNA
Atrium Therapeutics, Inc.Company with tickers: RNA
CIK
2093101
CUSIP
04965N104
Shares Outstanding
17,105,643
13F Activity (30d)
116 filings
116 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $19,635,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $36,915,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $16,657,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-17,280,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-16,633,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-0.97 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-0.97 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |